NASDAQ:GNOM Global X Genomics & Biotechnology ETF (GNOM) Price, Holdings, & News → SHOCKING Crypto Leak… (From Crypto 101 Media) (Ad) Free GNOM Stock Alerts $10.15 -0.06 (-0.59%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$10.12▼$10.3750-Day Range$9.68▼$11.4352-Week Range$8.63▼$13.08Volume61,133 shsAverage Volume65,515 shsMarket Capitalization$92.57 millionAssets Under Management$92.72 millionDividend Yield0.00%Net Expense Ratio0.50% Stock AnalysisStock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestTrendsStock AnalysisChartDividendHeadlinesHoldingsOptions ChainOwnershipRatingsShort InterestTrends Get Global X Genomics & Biotechnology ETF alerts: Email Address About Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center. Its customers include some of the global academic and government research centers and biopharmaceutical companies. Effective March 18, 2013, BGI-Shenzhen announced that through its wholly-owned subsidiary, Beta Acquisition Corporation, it has completed the acquisition of the Company.Read More GNOM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GNOM ETF News HeadlinesMay 2, 2024 | investorplace.com3 Gene Editing Stocks with the Potential to Make You an Overnight MillionaireApril 18, 2024 | markets.businessinsider.comThe Analyst Landscape: 4 Takes On 10x GenomicsMarch 21, 2024 | investorplace.com3 Stocks That Could Be the Next Big Thing in Gene EditingMarch 14, 2024 | finance.yahoo.comGlobal X Genomics & Biotechnology UCITS ETF (GNOG.L)March 6, 2024 | investing.comGlobal X Genomics & Biotechnology ETF (GNOM)December 29, 2023 | msn.comGlobal X Cannabis ETF declares $0.1656 dividendMay 12, 2023 | investing.comGlobal X S&P 500® Catholic Values ETF (CATH)April 29, 2023 | benzinga.comGlobal X Genomics & Biotechnology ETF (NASDAQ:GNOM), Quotes and News SummarySee More Headlines Receive GNOM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Global X Genomics & Biotechnology ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address Fund Details IssuerGlobal X Fund NameGlobal X Genomics & Biotechnology ETF Tax ClassificationRegulated Investment Company Stock ExchangeNASDAQCurrent SymbolNASDAQ:GNOM Inception Date4/5/2019 Fund ManagerChang Kim, James Ong, Nam To, Wayne Xie Webwww.completegenomics.com Phone+1-650-9432800Fund Focus Asset ClassEquity BenchmarkSolactive Genomics Index CategoryStrategy FocusTheme Development LevelBlended Development RegionGlobal Number of Holdings44 Fund Statistics Assets Under Management$92.72 million Average Daily Volume$0.00 Discount/Premium-0.02% Administrator, Advisor and Custodian AdministratorGlobal X Management Company LLC AdvisorGlobal X Management Company LLC CustodianBrown Brothers Harriman & Co. DistributorSEI Investments Distribution Co. Transfer AgentBrown Brothers Harriman & Co. TrusteeN/A Lead Market MakerSusquehanna Options OptionableN/A Short Interest14,400 shs Miscellaneous Outstanding Shares9,120,000Beta1.03 Creation Unit50,000 Creation Fee$500.00 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Ad Porter & CompanyThe only financial event in 2024 that matters Man Who Predicted 2008 Crash Warns of Black Swan Financial Event in 2024 Porter Stansberry’s new documentary is going viral.Stream the documentary for free by clicking here Global X Genomics & Biotechnology ETF ExpensesTypeGNOMTheme ETFsEquity ETFsNASDAQ ETFsAll ETFsManagement Fee0.50%0.57%0.54%0.48%0.51%Other Expenses0.00%0.72%0.54%0.34%0.58%Total Expense0.50%0.72%0.70%0.58%0.70%Fee Waiver0.00%-0.76%-0.55%-0.22%-0.56%Net Expense0.50%0.59%0.60%0.54%0.58% Global X Genomics & Biotechnology ETF (GNOM) Holdings & ExposureTop 10 GNOM HoldingsModerna(NASDAQ:MRNA)Holding Weight: 5.69%Bio-Techne(NASDAQ:TECH)Holding Weight: 4.78%Natera(NASDAQ:NTRA)Holding Weight: 4.44%Intellia Therapeutics(NASDAQ:NTLA)Holding Weight: 4.37%BioNTech(NASDAQ:BNTX)Holding Weight: 4.24%Agilent Technologies(NYSE:A)Holding Weight: 4.14%Arrowhead Pharmaceuticals(NASDAQ:ARWR)Holding Weight: 4.00%Qiagen(NYSE:QGEN)Holding Weight: 3.93%Alnylam Pharmaceuticals(NASDAQ:ALNY)Holding Weight: 3.92%Sarepta Therapeutics(NASDAQ:SRPT)Holding Weight: 3.86%GNOM Sector ExposureGNOM Industry ExposureFull Holdings Details Similar ETFsWisdomTree Cybersecurity FundNASDAQ:WCBRWahed Dow Jones Islamic World ETFNASDAQ:UMMAVictoryShares THB Mid Cap ETFNASDAQ:MDCPValkyrie Bitcoin Miners ETFNASDAQ:WGMIFirst Trust Indxx Innovative Transaction & Process ETFNASDAQ:LEGRInstitutional OwnershipManhattan West Asset Management LLCSold 10,711 shares on 5/15/2024Ownership: 0.298%Banco Santander S.A.Sold 9,050 shares on 5/10/2024Ownership: 0.177%Portland Global Advisors LLCBought 1,450 shares on 5/9/2024Ownership: 2.654%Oppenheimer Asset Management Inc.Sold 1,051 shares on 5/7/2024Ownership: 0.674%Insight Advisors LLC PABought 13,316 shares on 5/7/2024Ownership: 0.146%View All Institutional Transactions GNOM ETF - Frequently Asked Questions How have GNOM shares performed in 2024? Global X Genomics & Biotechnology ETF's stock was trading at $11.56 on January 1st, 2024. Since then, GNOM stock has decreased by 12.2% and is now trading at $10.15. View the best growth stocks for 2024 here. Are investors shorting Global X Genomics & Biotechnology ETF? Global X Genomics & Biotechnology ETF saw a drop in short interest in May. As of May 15th, there was short interest totaling 14,400 shares, a drop of 22.6% from the April 30th total of 18,600 shares. Based on an average daily volume of 76,300 shares, the days-to-cover ratio is currently 0.2 days. View Global X Genomics & Biotechnology ETF's Short Interest. What does GNOM invest in? Global X Genomics & Biotechnology ETF is a equity fund issued by Global X. GNOM focuses on theme investments and follows the Solactive Genomics Index. The fund's investments total to approximately $92.72 million assets under management. What stocks does Global X Genomics & Biotechnology ETF hold? GNOM invests in 44 holdings. Some of the stocks in their portfolio include Moderna (MRNA), Bio-Techne (TECH), Natera (NTRA), Intellia Therapeutics (NTLA), BioNTech (BNTX), Agilent Technologies (A), Arrowhead Pharmaceuticals (ARWR), Qiagen (QGEN), Alnylam Pharmaceuticals (ALNY) and Sarepta Therapeutics (SRPT). What is the management fee for Global X Genomics & Biotechnology ETF? Global X Genomics & Biotechnology ETF's management fee is 0.50% and has no other recorded expenses or fee waivers. The net expense ratio for GNOM is 0.50%. What other stocks do shareholders of Global X Genomics & Biotechnology ETF own? Based on aggregate information from My MarketBeat watchlists, some companies that other Global X Genomics & Biotechnology ETF investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Intel (INTC), Pfizer (PFE), Quest Diagnostics (DGX), Micron Technology (MU), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB). Who are Global X Genomics & Biotechnology ETF's major shareholders? Global X Genomics & Biotechnology ETF's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Mirae Asset Global Investments Co. Ltd. (4.14%), Raymond James Financial Services Advisors Inc. (2.89%), Portland Global Advisors LLC (2.65%), Sightline Wealth Advisors LLC (0.68%), Oppenheimer Asset Management Inc. (0.67%) and McGuire Investment Group LLC (0.64%). How do I buy shares of Global X Genomics & Biotechnology ETF? Shares of GNOM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:GNOM) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersBiden Nomination CANCELED?The Freeport SocietyWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Global X Genomics & Biotechnology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.